In the closing of the recent trading day, Hologic (HOLX) stood at $71.19, denoting a +1.17% change from the preceding trading day.

In the closing of the recent trading day, Hologic (HOLX) stood at $70.20, denoting a -0.13% change from the preceding trading day.

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025.

In the closing of the recent trading day, Hologic (HOLX) stood at $72.73, denoting a +0.05% change from the preceding trading day.

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #gynesonics--Hologic Completes Acquisition of Gynesonics, Inc.

Hologic (HOLX) concluded the recent trading session at $71.74, signifying a -0.49% move from its prior day's close.

Hologic's strength in the Surgical wing instills optimism among investors. Yet, currency impacts raise concerns.

Via an agreement with the CDC, Hologic is set to develop ASRs for launching the H5N1 bird flu test.

Despite the current challenges, HOLX's portfolio strength and international growth prospects make it worth holding on to.

HOLX will unveil breakthrough innovations at this year's RSNA, focusing on imaging solutions and AI.

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

HOLX's strength in the Molecular Diagnostics wing instills optimism among investors. Yet, macro woes and currency impacts raise concerns.

Despite the recent earnings miss, Hologic's portfolio strength and capital allocation strategy can be appealing to investors.

HOLX's fiscal 2024 fourth-quarter results underscore the durable growth of its businesses.

Hologic (HOLX) came out with quarterly earnings of $1.01 per share, missing the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.89 per share a year ago.